UY37969A - Formulaciones de peptidos de liberación sostenida - Google Patents

Formulaciones de peptidos de liberación sostenida

Info

Publication number
UY37969A
UY37969A UY0001037969A UY37969A UY37969A UY 37969 A UY37969 A UY 37969A UY 0001037969 A UY0001037969 A UY 0001037969A UY 37969 A UY37969 A UY 37969A UY 37969 A UY37969 A UY 37969A
Authority
UY
Uruguay
Prior art keywords
sustained release
formulations
setmelanotide
release peptides
pharmaceutical composition
Prior art date
Application number
UY0001037969A
Other languages
English (en)
Inventor
John Dey Michael
Jaya Gautam
T Henderson Barton
Markus Johnsson
Stina Lindman
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of UY37969A publication Critical patent/UY37969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta divulgación proporciona, al menos en parte un producto farmacéutico que comprende setmelanotide; u otra composición farmacéutica que tiene su mecanismo de acción principal en el receptor MC4 como un agonista y un excipiente, por ejemplo, un excipiente lipídico, y / o un vehículo farmacéuticamente aceptable. El producto farmacéutico descrito en el presente documento proporciona una liberación sostenida de setmelanotide u otra composición farmacéutica, que puede dar como resultado un perfil farmacocinético y farmacodinámico más deseable tras la administración.
UY0001037969A 2017-11-15 2018-11-15 Formulaciones de peptidos de liberación sostenida UY37969A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762586643P 2017-11-15 2017-11-15

Publications (1)

Publication Number Publication Date
UY37969A true UY37969A (es) 2019-06-28

Family

ID=66539115

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037969A UY37969A (es) 2017-11-15 2018-11-15 Formulaciones de peptidos de liberación sostenida

Country Status (16)

Country Link
US (1) US20210169965A1 (es)
EP (1) EP3710041A4 (es)
JP (2) JP2021502983A (es)
KR (1) KR20200135280A (es)
CN (1) CN112188898A (es)
AR (1) AR113885A1 (es)
AU (1) AU2018370039A1 (es)
BR (1) BR112020009648A2 (es)
CA (1) CA3082708A1 (es)
IL (1) IL274689A (es)
MX (1) MX2020005117A (es)
RU (1) RU2020119425A (es)
SG (1) SG11202004373RA (es)
TW (1) TW201922278A (es)
UY (1) UY37969A (es)
WO (1) WO2019099735A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005008247D1 (de) * 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
MY177820A (en) * 2011-05-25 2020-09-23 Camurus Ab Controlled release peptide formulations
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
CN107257681A (zh) * 2014-12-23 2017-10-17 卡姆拉斯公司 控释配制品
EP3356386B1 (en) * 2015-09-30 2024-02-14 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders

Also Published As

Publication number Publication date
CA3082708A1 (en) 2019-05-23
JP2024026333A (ja) 2024-02-28
RU2020119425A (ru) 2021-12-15
CN112188898A (zh) 2021-01-05
EP3710041A4 (en) 2021-08-18
BR112020009648A2 (pt) 2020-11-10
WO2019099735A1 (en) 2019-05-23
SG11202004373RA (en) 2020-06-29
IL274689A (en) 2020-06-30
KR20200135280A (ko) 2020-12-02
US20210169965A1 (en) 2021-06-10
MX2020005117A (es) 2020-11-24
EP3710041A1 (en) 2020-09-23
JP2021502983A (ja) 2021-02-04
TW201922278A (zh) 2019-06-16
AR113885A1 (es) 2020-06-24
AU2018370039A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
PA8842701A1 (es) Granulado que contiene nicotina
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
PA8815501A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
CR20110110A (es) Composicion farmaceutica
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
BR112012029912A2 (pt) vácinas de combinação de nanotransportadores sintéticos
CL2008000306A1 (es) Dispositivo para administrar medicamentos que comprende un cuerpo con una matriz de una silicona y un medicamento oftalmico, el cuerpo que tiene una superficie externa, un revestimiento de parileno en una parte de la superficie externa del cuerpo; y
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
ECSP19035322A (es) Formulaciones farmacéuticas
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
UY37969A (es) Formulaciones de peptidos de liberación sostenida
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MX2018008300A (es) Formulacion para anticuerpo y conjugado de farmaco del mismo.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2008000617A1 (es) Composicion farmaceutica que comprende a un agente calcilitico adminstrado oralmente, induce liberacion rapida y de corta duracion de la hormona paratiroide en el plasma; y proceso para la preparacion de la composicion farmaceutica.
WO2017046227A3 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
BR112012008983A2 (pt) "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol."
ECSP18008411A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
BR112021023012A2 (pt) Coformulações injetáveis à base de ciclodextrina de inibidores de sglt2 e peptídeos de incretina